These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1867 related articles for article (PubMed ID: 31443960)

  • 41. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
    Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
    Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
    Mori K; Miura N; Babjuk M; Karakiewicz PI; Mostafaei H; Laukhtina E; Quhal F; Motlagh RS; Pradere B; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 Oct; 38(10):774-782. PubMed ID: 32654948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
    Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
    Neuzillet Y; Pradère B; Xylinas E; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Roumiguié M; Seisen T; Traxer O; Leon P; Roupret M
    Prog Urol; 2022 Nov; 32(15):1102-1140. PubMed ID: 36400479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Miyake M; Nishimura N; Fujii T; Fujimoto K
    Int J Urol; 2023 Nov; 30(11):944-957. PubMed ID: 37522629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
    Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
    Arnaud Q; Sebe P; Colau A; Mouton M; Desgrandchamps F; Masson-Lecomte A; Bessede T; Irani J; Dominique I
    Fr J Urol; 2024 Jan; 34(1):102548. PubMed ID: 37980231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
    van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
    Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
    Contieri R; Hurle R; Paciotti M; Casale P; Saita A; Porpiglia F; Fiori C; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Cantiello F; Damiano R; Borghesi M; Bove P; Bertolo R; Papalia R; Mari A; Luzzago S; Mistretta FA; Soria F; Gontero P; Marchioni M; LA Civita E; Terracciano D; Russo GI; Schips L; Perdona S; Mirone V; Tataru OS; Musi G; Vartolomei MD; Autorino R; Montanari E; DE Cobelli O; Ferro M
    Minerva Urol Nephrol; 2023 Apr; 75(2):180-187. PubMed ID: 36197700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
    De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
    Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
    Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
    Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.
    Tomida R; Miyake M; Minato R; Sawada Y; Matsumura M; Iida K; Hori S; Fukui S; Ohyama C; Miyake H; Hongo F; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Hashine K;
    Int J Clin Oncol; 2022 May; 27(5):958-968. PubMed ID: 35142962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 94.